**Background of PELP1 Antibody**
PELP1 (Proline-, Glutamic acid-, and Leucine-rich Protein 1), also known as PHF20. is a scaffolding protein involved in transcriptional regulation, signal transduction, and epigenetic modifications. It interacts with nuclear receptors (e.g., estrogen receptor, ER) and chromatin-modifying complexes, acting as a coactivator to regulate hormone-responsive gene expression. PELP1 is critical in cell proliferation, survival, and differentiation, with dysregulation linked to cancers, particularly hormone-dependent malignancies like breast and ovarian cancer. Overexpression of PELP1 correlates with tumor progression, therapy resistance, and metastasis, often via aberrant activation of oncogenic pathways (e.g., PI3K/AKT, MAPK).
PELP1 antibodies are essential tools for detecting PELP1 expression and localization in research. They enable the study of its role in cancer biology, hormone signaling, and epigenetic regulation through techniques like Western blotting, immunohistochemistry, and co-immunoprecipitation. These antibodies help identify PELP1’s interactions with partners (e.g., histone modifiers, kinases) and its post-translational modifications, which influence its oncogenic functions. Developing specific PELP1 antibodies has advanced therapeutic targeting strategies, as inhibiting PELP1-associated pathways may offer potential in treating cancers with PELP1 dysregulation.